<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814450</url>
  </required_header>
  <id_info>
    <org_study_id>ASNG-LFNA-101-IL</org_study_id>
    <nct_id>NCT00814450</nct_id>
  </id_info>
  <brief_title>Safety &amp; Accuracy of the ActiSight Needle Guidance System in Percutaneous Chest Aspiration and Biopsy</brief_title>
  <acronym>ANGS-PCAB</acronym>
  <official_title>A Prospective, Open-Label, Single-Arm, Single-Center Study Evaluating The Preliminary Safety And Accuracy Of The Actisight™ Needle Guidance System In Patients Undergoing CT-Guided Percutaneous Chest Aspiration And Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ActiViews Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ActiViews Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to provide clinical data regarding safety and accuracy of the&#xD;
      ActiSight™ Needle Guidance System in assisting Chest CT guided biopsies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of target reached within a radius of 8 mm from the preplanned targeted point as measured on the final CT scan.</measure>
    <time_frame>Measure evaluated during entire course of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of needle punctures through the skin</measure>
    <time_frame>Measure evaluated during entire course of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of needle punctures through the pleura</measure>
    <time_frame>Measure evaluated during entire course of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CT scans needed</measure>
    <time_frame>Measure evaluated during entire course of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radial distance at target plane at the needle's final position as shown on the ActiSight screen</measure>
    <time_frame>Measure evaluated during entire course of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events following the procedure, including the following:Pneumothorax, Hemoptysis &gt;100 ml, Bleeding, Collapsed lung, Chest drainage, Need for hospitalization</measure>
    <time_frame>Measure evaluated during entire course of study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Biopsy</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biopsy needle guidance system (ActiSight™)</intervention_name>
    <description>The ActiSight system assists in guiding an aspiration or biopsy needle, to a designated point within the body by means of CT visualization.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects, 18 years of age or older at the time of enrollment&#xD;
&#xD;
          -  Subjects meeting all medical conditions for percutaneous chest aspiration/biopsy with&#xD;
             safe path to lesion between ribs, however, not in the breast area in women or men with&#xD;
             gynecomastia&#xD;
&#xD;
          -  Single target pulmonary lesion greater than 10 mm in size (diameter) and depth of&#xD;
             lesion greater than 40 mm from the skin&#xD;
&#xD;
          -  INR &lt;1.3&#xD;
&#xD;
          -  Written informed consent to participate in the study&#xD;
&#xD;
          -  Ability to comply with the requirements of the study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fibrous tissue or cyst in access path (not including target lesion)&#xD;
&#xD;
          -  Hemophilia, thrombocytopenia, coagulopathy, or other elevated risk for bleeding or&#xD;
             abnormal clotting&#xD;
&#xD;
          -  Central lesion is located in radius of less than 2 cm from lobar blood vessels and the&#xD;
             heart.&#xD;
&#xD;
          -  The selected needle path has a safety margin of less than 2 cm from major blood&#xD;
             vessels and the heart&#xD;
&#xD;
          -  Use of ticlopidine or similar antithrombotic medication&#xD;
&#xD;
          -  For subjects taking warfarin or other anticoagulant medication, INR &gt;1.3&#xD;
&#xD;
          -  Pulmonary hypertension, heart failure, renal failure, or blood dyscrasia&#xD;
&#xD;
          -  Subjects who cannot tolerate mild sedation&#xD;
&#xD;
          -  Subjects with FEV1 &lt; 800 mL unless approved by principal investigator following&#xD;
             consultation with multidisciplinary team&#xD;
&#xD;
          -  Subjects with the following laboratory values, unless approved by hematologist:&#xD;
&#xD;
               -  Platelet count &lt;100,000/mL&#xD;
&#xD;
               -  APTT &gt;39 sec or PT &gt;15 sec&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Patient is unable to comply with requirements of the procedure, i.e. holding breath&#xD;
&#xD;
          -  Participation in an investigational trial within 30 days of enrollment&#xD;
&#xD;
          -  Any form of substance abuse (including drug or alcohol abuse), psychiatric disorder,&#xD;
             or any chronic condition that could, in the opinion of the investigator, of&#xD;
             interfering with the conduct of the study.&#xD;
&#xD;
          -  Subjects who are uncooperative or cannot follow instructions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boaz Tiran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel-Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>December 23, 2008</study_first_submitted>
  <study_first_submitted_qc>December 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2008</study_first_posted>
  <last_update_submitted>December 29, 2009</last_update_submitted>
  <last_update_submitted_qc>December 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Uri Shreter/ Medical Director</name_title>
    <organization>Activiews</organization>
  </responsible_party>
  <keyword>Biopsy</keyword>
  <keyword>Fine needle aspiration</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

